William G. Wierda

4.8k total citations · 1 hit paper
44 papers, 2.1k citations indexed

About

William G. Wierda is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, William G. Wierda has authored 44 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 28 papers in Pathology and Forensic Medicine and 17 papers in Immunology. Recurrent topics in William G. Wierda's work include Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (28 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). William G. Wierda is often cited by papers focused on Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (28 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). William G. Wierda collaborates with scholars based in United States, United Kingdom and France. William G. Wierda's co-authors include Michael J. Keating, Hagop M. Kantarjian, Susan O’Brien, Francis J. Giles, Deborah A. Thomas, Charles Koller, Thomas J. Kipps, John G. Gribben, Laura Z. Rassenti and Susan Lerner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

William G. Wierda

37 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

2005 704 citations Michael J. Keating, Susan O’Brien et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William G. Wierda United States	18	1.8k	1.4k	948	358	351	44	2.1k
Mohammed Farooqui United States	17	1.3k 0.7×	964 0.7×	746 0.8×	293 0.8×	346 1.0×	53	1.6k
Sarah E. M. Herman United States	19	2.1k 1.2×	1.6k 1.2×	1.0k 1.1×	504 1.4×	574 1.6×	42	2.5k
Ilaria Del Giudice Italy	24	1.5k 0.8×	1.3k 0.9×	764 0.8×	408 1.1×	305 0.9×	82	1.9k
Ben Kennedy United Kingdom	15	1.2k 0.7×	1.1k 0.8×	778 0.8×	209 0.6×	268 0.8×	26	1.5k
Guillermo Dighiero Uruguay	11	1.3k 0.8×	970 0.7×	793 0.8×	178 0.5×	235 0.7×	15	1.7k
Jacqueline C. Barrientos United States	27	2.3k 1.3×	1.9k 1.4×	995 1.0×	630 1.8×	672 1.9×	178	2.9k
Marta Crespo Spain	19	1.5k 0.9×	1.3k 0.9×	925 1.0×	619 1.7×	242 0.7×	52	2.7k
Monica Else United Kingdom	22	1.6k 0.9×	1.2k 0.9×	712 0.8×	403 1.1×	320 0.9×	42	2.0k
Manfred Hensel Germany	21	988 0.6×	903 0.6×	517 0.5×	490 1.4×	310 0.9×	68	1.6k
Mariela Sivina United States	18	1.5k 0.8×	947 0.7×	778 0.8×	367 1.0×	471 1.3×	39	2.0k

Countries citing papers authored by William G. Wierda

Since Specialization

Citations

This map shows the geographic impact of William G. Wierda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Wierda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Wierda more than expected).

Fields of papers citing papers by William G. Wierda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William G. Wierda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Wierda. The network helps show where William G. Wierda may publish in the future.

Co-authorship network of co-authors of William G. Wierda

This figure shows the co-authorship network connecting the top 25 collaborators of William G. Wierda. A scholar is included among the top collaborators of William G. Wierda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William G. Wierda. William G. Wierda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kantarjian, Hagop M., Gautam Borthakur, Naval Daver, et al.. (2025). A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens. Cancer. 131(21). e70113–e70113.

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S346–S346. 3 indexed citations

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S180–S180. 1 indexed citations

Swaminathan, Mahesh, Koji Sasaki, Guilin Tang, et al.. (2024). Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia. Blood. 144(Supplement 1). 3246–3246.

Alousi, Amin M., Jennifer Freeman, Alison Gulbis, et al.. (2024). Enabling efficient patient discharge with a mindset, toolset, and skillset framework.. JCO Oncology Practice. 20(10_suppl). 33–33.

Davids, Matthew S., John M. Burke, Vivek S. Chopra, et al.. (2024). BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia. Blood. 144(Supplement 1). 3257.2–3257.2. 1 indexed citations

Ahmed, Sairah, Sheeba K. Thomas, Luis Fayad, et al.. (2023). Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia. 23(8). 610–615. 7 indexed citations

Vangapandu, Hima V., Ondřej Havránek, Mary Ayres, et al.. (2017). B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Molecular Cancer Research. 15(12). 1692–1703. 40 indexed citations

Vitale, Candida, Lorenzo Falchi, Elisa ten Hacken, et al.. (2016). Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical Cancer Research. 22(10). 2359–2367. 23 indexed citations

10.

Cui, Bing, Emanuela M. Ghia, Liguang Chen, et al.. (2016). High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 128(25). 2931–2940. 110 indexed citations

11.

Pemmaraju, Naveen, Preetesh Jain, L. Jeffrey Medeiros, et al.. (2016). PET‐positive lymphadenopathy in CLL—Not always Richter transformation. American Journal of Hematology. 92(4). 405–406. 7 indexed citations

12.

Struemper, Herbert, Mark Sale, Bela Patel, et al.. (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. The Journal of Clinical Pharmacology. 54(7). 818–827. 22 indexed citations

13.

Mehta, Rohtesh S., Antonio Di Stasi, Chitra Hosing, et al.. (2014). Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 14(3). e105–e109. 2 indexed citations

14.

Kharfan‐Dabaja, Mohamed A., William G. Wierda, & Laurence J.N. Cooper. (2013). Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia. 28(3). 507–517. 16 indexed citations

15.

Badoux, Xavier C., Michael J. Keating, Sijin Wen, et al.. (2012). Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 31(5). 584–591. 113 indexed citations

16.

Wierda, William G., Nicholas Chiorazzi, Claire Dearden, et al.. (2010). Chronic Lymphocytic Leukemia: New Concepts for Future Therapy. Clinical Lymphoma Myeloma & Leukemia. 10(5). 369–378. 9 indexed citations

17.

Sargent, Rachel L., Dan Jones, Lynne V. Abruzzo, et al.. (2008). Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics. 11(1). 25–34. 30 indexed citations

18.

Ferrajoli, Alessandra, William G. Wierda, Ruth LaPushin, et al.. (2007). Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia. European Journal Of Haematology. 80(4). 296–298. 6 indexed citations

19.

Widhopf, George F., Traci L. Toy, Laura Z. Rassenti, et al.. (2007). Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 111(6). 3137–3144. 37 indexed citations

20.

Wierda, William G.. (2006). Current and Investigational Therapies for Patients with CLL. Hematology. 2006(1). 285–294. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact